National Technical Services for Multi-site Collaborative Cancer Clinical Trials Groups

The Australian Government through Cancer Australia has funded the following National Technical Services to assist the Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) supported by Cancer Australia under the Support for Cancer Clinical Trials Program to develop industry-independent cancer clinical trial protocols.

Health and Pharmaco-economic Technical Services

Provides the CTGs with high quality, expert advice and technical services relating to the consistent inclusion of appropriate health and pharmaco-economic measures or sub-studies into all new industry-independent cancer clinical trials protocols developed.

These services assist the CTGs to incorporate appropriate health and pharmaco-economic analyses into new cancer clinical trials leading to greater economic evidence for future decision-making. 

Cancer Australia Chair in Quality-of-Life and Quality-of-Life Technical Services

Provides the CTGs with access to high quality, expert advice and technical support services relating to the consistent inclusion of appropriate quality-of-life measures or sub-studies into all new industry-independent cancer clinical trial protocols developed. 

A diagnosis of cancer and its treatment has considerable impact on the quality-of-life of individuals, their families and carers.  Incorporation of quality-of-life measures or sub-studies into all new clinical trials helps identify effective interventions which can improve cancer outcomes whilst ensuring that the patient impact of new or modified interventions is assessed and understood.

Genomic Cancer Clinical Trial Initiative (GCCTI)

Provides the CTGs with expert advice and technical services relating to the development of cancer clinical trial protocols that specifically target cancer mutations/molecular markers across a range of tumour types. Many tumours from different sites of origin have cancer mutations/molecular markers in common and the prognostic outcome of treatment can often be improved by targeting these mutations/molecules. 

Collaborative development of cancer clinical trials protocols for mutations/molecular markers which are common to several tumour types will increase our understanding of the effectiveness of targeted prevention and/ or treatment interventions, supporting the delivery of efficient evidence-based best-practice care.

Asia Pacific Clinical Oncology Research Development Initiative (ACORD)

Provides  CTGS with access to education in clinical trials research design and development that addresses the changing grant application requirements of competitive funders of clinical trials research.

It is anticipated that members of the CTGs supported by Cancer Australia will attend the ACORD workshops. 

Cancer and Supportive Care Clinical Studies Collaborative (CSCCSC)

Will work with CTGs to develop industry-independent cancer clinical trial protocols to the stage of application for grant funding to conduct the clinical trials.  The clinical trial protocols will focus on supportive care and symptom control for patients with a cancer diagnosis across a range of cancer types.

Collaborative development of cancer clinical trials protocols which focus on supportive care and symptom control will increase our understanding of the effectiveness of therapies/ interventions to manage the symptoms of patients with a diagnosis of advanced cancer.